Clinical Report: Evaluation of Patency Rates in Aortoiliac Disease Stenting
Overview
This study evaluates the primary patency rates of balloon-expandable, self-expanding, and covered stents in patients with aortoiliac disease. Results indicate that while balloon-expandable stents showed a slight advantage at one year, this difference did not persist at three years, suggesting stent selection should be based on other factors.
Background
Peripheral arterial disease (PAD) affects millions in the U.S., with a significant proportion involving the iliac arteries. Effective treatment options are critical as the incidence of PAD is expected to rise with an aging population. Understanding the comparative effectiveness of different stent types can guide clinical decision-making in managing aortoiliac disease.
Data Highlights
Stent Type
1-Year Patency Rate
3-Year Patency Rate
Balloon-Expandable
98.4%
Not significant
Self-Expanding
97.1%
Not significant
Covered
96.3%
Not significant
Key Findings
The majority of stents implanted were balloon-expandable (58%).
Technical success rates exceeded 99% across all stent types.
One-year primary patency rates were 98.4% for balloon-expandable, 97.1% for self-expanding, and 96.3% for covered stents (P = 0.03).
No significant differences in three-year primary patency rates were observed (P = 0.17).
Stent selection should consider cost, lesion characteristics, and operator judgment rather than solely long-term patency outcomes.
Clinical Implications
Clinicians should weigh the advantages and limitations of each stent type when treating aortoiliac disease. Given the lack of significant long-term differences in patency, factors such as cost and individual patient anatomy may play a more critical role in stent selection.
Conclusion
This study underscores the importance of individualized stent selection in aortoiliac interventions, as long-term patency rates do not significantly differ among stent types.
A large English cohort study found influenza hospitalization more than doubled the short-term risk of new-onset diabetes, with prediabetes and critical care admission among the strongest predictors.
In a cohort study reported in JAMA Oncology, Fox et al found that approximately half of older patients with metastatic non–small cell lung cancer (NSCLC) have received systemic therapy in the United S...
